SUBSCRIBE
SUBSCRIBE

Anavex Life Sciences Corp.

NEWS
TRICON: Clinical Exome Sequencing More Efficient and Unbiased, Says Pathologist
Drug Development
TRICON: Alzheimer’s Drug Saw 80% Reversal in Memory Loss, Say Anavex CEO
February 18, 2015
 · 
2 min read
Load More
JOBS
IN THE PRESS
Press Releases
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
March 23, 2026
 · 
6 min read
Press Releases
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease
March 20, 2026
 · 
6 min read
Press Releases
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
March 17, 2026
 · 
5 min read
Press Releases
Anavex Life Sciences to Present at the Citizens Life Sciences Conference
March 3, 2026
 · 
3 min read
Press Releases
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
February 25, 2026
 · 
3 min read
Press Releases
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
February 23, 2026
 · 
4 min read
Press Releases
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
February 9, 2026
 · 
9 min read
Press Releases
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
February 3, 2026
 · 
3 min read
Press Releases
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
January 13, 2026
 · 
6 min read
Press Releases
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
January 8, 2026
 · 
5 min read
Load More